Alessandra Bortoluzzi
Overview
Explore the profile of Alessandra Bortoluzzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Garaffoni C, Tamussin M, Calciolari I, Lanza G, Bortoluzzi A, Scire C, et al.
Front Immunol
. 2024 Jan;
14:1298583.
PMID: 38274811
Background: Inflammatory arthritis (IAs), such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), are characterized by the presence of chronic synovitis. The Krenn's synovitis score (KSS), a simple tool detectable...
12.
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, et al.
Ann Rheum Dis
. 2024 Jan;
83(4):464-474.
PMID: 38233103
Objectives: Treatment targets in systemic lupus erythematosus (SLE) have been validated in unselected-in terms of severity-cohorts, which limits their generalisability. We assessed remission (Definition of Remission in SLE (DORIS)) and...
13.
Silvagni E, Missiroli S, Patergnani S, Boncompagni C, DUgo C, Garaffoni C, et al.
J Autoimmun
. 2023 Dec;
143:103159.
PMID: 38141420
Objectives: To evaluate the in vitro effect of tofacitinib on autophagy activity of psoriatic arthritis (PsA) fibroblast-like synoviocytes (FLS), and to confirm its activity on inflammatory and invasive properties of...
14.
Garaffoni C, Adinolfi A, Bortoluzzi A, Filippou G, Giollo A, Sakellariou G, et al.
Clin Exp Rheumatol
. 2023 Jul;
41(11):2129-2141.
PMID: 37497719
New evidence from 2022 slightly changed some perspectives for rheumatoid arthritis (RA) management. Real-world data on the efficacy and safety of disease-modifying anti-rheumatic drugs strengthened the importance of tailoring treatment...
15.
Abhishek A, Tedeschi S, Pascart T, Latourte A, Dalbeth N, Neogi T, et al.
Ann Rheum Dis
. 2023 Jul;
82(10):1248-1257.
PMID: 37495237
Objective: Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and...
16.
Abhishek A, Tedeschi S, Pascart T, Latourte A, Dalbeth N, Neogi T, et al.
Arthritis Rheumatol
. 2023 Jul;
75(10):1703-1713.
PMID: 37494275
Objective: Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and...
17.
Galoppini G, Marangoni A, Cirilli F, Ruffilli F, Garaffoni C, Govoni M, et al.
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373752
Systemic lupus erythematosus (SLE) is characterized by multisystemic clinical manifestations ranging from a relatively mild involvement to potentially life-threatening complications. Due to this complexity, a multidisciplinary (MD) approach is the...
18.
Battaglia Y, Bellasi A, Esposito P, Bortoluzzi A, Rotondi S, Andreucci M, et al.
Biomolecules
. 2023 May;
13(4).
PMID: 37189376
Although reduced bone mineral density (BMD) is associated with a higher risk of fractures, morbidity, and mortality in kidney transplant patients (KTRs), there is no consensus on optimal treatment for...
19.
Zucchi D, Silvagni E, Elefante E, Signorini V, Cardelli C, Trentin F, et al.
Clin Exp Rheumatol
. 2023 May;
41(5):997-1008.
PMID: 37133502
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of clinical manifestations and a relapsing-remitting course. New data regarding pathogenic pathways, biomarkers and clinical manifestations of...
20.
Zen M, Gatto M, Depascale R, Regola F, Fredi M, Andreoli L, et al.
J Pers Med
. 2023 Apr;
13(4).
PMID: 37109077
Aim: To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods: All patients with skin and joint involvement enrolled in...